About Us

GeneCentric Company Overview

GeneCentric Therapeutics is applying our proprietary rT(I)ME Explorer Platform to identify high resolution molecular subtypes and drug responder populations that enable the development of precision cancer drugs while improving patient outcomes. Our approach applies our rT(I)ME Explorer Platform to parse the complexity of the tumor and the immune microenvironment and overall tumor biology to generate response  signatures. This approach yields high-resolution cancer subtypes with the potential to function as universal biomarkers, or predictive response signatures, for immune-based, targeted and other cancer therapeutics. In commercializing our technology through strategic collaborations with pharmaceutical and biotech companies, we can deploy the rT(I)ME Explorer Platform at all stages of the drug development cycle.

Kirk_Beebe

Kirk Beebe, PhD

Chief Scientific Officer




Philippe_Chemla

Philippe Chemla, PhD, MBA

Chief Business Officer




James M Davison, PhD

Senior Translational Genomics Scientist




Jeff Burdine

Sr. Director Information Technology




Joel R. Eisner, PhD

Sr. Vice President - Clinical & Corporate Development




Felix Frueh, PhD

Genomics Application and Regulatory Expert Executive Partner, Opus Three Life Sciences




John Guo

John Guo, PhD

Senior Bioinformatics Scientist




Howard_Kartstein

Howard Kartstein

Director of Business Development




Myla Lai-Goldman, MD

Founder & Executive Chairperson




Greg Mayhew, DrPH

Director of Bioinformatics




Mike Milburn

Michael V. Milburn, PhD

Chief Executive Officer and President




Joel Parker, PhD

Bioinformatics, RNA, and expression analysis expert Associate Professor, UNC-Chapel Hill




Paul Armistead, MD, PhD

Immunology, Hematologist and Antigen Expert Associate Professor of Medicine, UNC-Chapel Hill




Chenyqua Shepard, CPA

Chief Operating Officer




Yoichiro Shibata, PhD

Senior Bioinformatics Scientist




Josh Uronis, PhD

Laboratory Director




Benjamin Vincent, MD

Hematologist and Immunogenomics Expert Assistant Professor of Medicine, UNC-Chapel Hill




Myla Lai-Goldman, MD

Founder & Executive Chairperson

Arnold J. Levine, Phd

Director

Ellen Lubman

Director

Mike Milburn

Michael V. Milburn, PhD

Chief Executive Officer and President

Charles M. Perou, PhD

Founder and Director

Clay B. Thorp

General Partner, Hatteras Venture Partners

N. Hayes

David Neil Hayes, MD MPH MS

Observer and Founder

Making News: Our Latest Progress, Partnerships and Impact

GeneCentric Therapeutics Closes $7.5 Million Series B1 Financing

LEARN MORE

Collaboration with Labcorp recently featured in the Triangle Business Journal

LEARN MORE

GeneCentric Therapeutics Collaborates with Labcorp to Develop Novel RNA-Based Oncology Diagnostics

LEARN MORE